{"id":24027,"date":"2013-12-01T11:48:05","date_gmt":"2013-12-01T11:48:05","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=24027"},"modified":"2013-12-06T08:55:04","modified_gmt":"2013-12-06T08:55:04","slug":"gsk744-24-week-results-with-oral-integrase-inhibitor-planned-for-once-monthly-injections","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/24027","title":{"rendered":"GSK744: 24-week results with oral integrase inhibitor planned for once-monthly injections"},"content":{"rendered":"

<\/strong>\"EACS<\/strong>Simon Collins, HIV i-Base<\/p>\n

Early results were also presented at EACS 2013 for ViiV Healthcare’s follow-up compound to dolutegravir, which currently has the development name GSK-744. [1]<\/strong><\/p>\n

Previous results with this integrase inhibitor have reported a sufficiently long half-life with both IV and SC injectible formulations to support once-monthly dosing both in therapeutic and PrEP prevention studies.<\/p>\n

Viral efficacy results from the LATTE study were from using the oral formulation of GSK-744 in combination with tenofovir\/FTC. Participants who become undetectable by week 24, roll over to use dual therapy with oral GSK-744 plus oral rilpivirine, out to 96 weeks. [2]<\/p>\n

The first part of the study was a randomised open label dose finding study comparing 10 mg, 30 mg and 60 mg of GSK-744 to a control arm of efavirenz plus tenofovir\/FTC. Approximately 60 patients were in each arm.<\/p>\n

Baseline median CD4 count was approximately 400 cells\/mm3 with mean viral load or 4.2 – 4.4 log copies\/mL Again, no data on the range or variance for the baseline data were included in the presentation, limiting the ability to interpret the results, although broadly people were in early HIV infection.<\/p>\n

At week 24, viral load reductions in the 10 mg, 30 mg, 60 mg and control arms were -2.53, -2.53, -2.50 and -1.88 log copies\/mL, respectively The percentage of patients (95% CI) with viral suppression to <50 copies\/mL was 88% (80%, 96%), 85% (76%, 94%), 87% (78%, 95%) and 74% (63%, 85%), respectively.<\/p>\n

Future development will go forward using the 30 mg dose.<\/p>\n

Comment<\/h3>\n

Given the approximate -2.2 log reductions seen following 10 days of monotherapy with GSK-744 and that tenofovir and FTC are included for six months with such a low baseline viral load, it is difficult to understand why a higher percentage of people had an undetectable viral load.<\/strong><\/p>\n

While ART is generally getting better, the target should be for near-100%.<\/strong><\/p>\n

References:<\/p>\n

    \n
  1. Margolis D et al. Once-daily oral GSK1265744 (GSK744) as part of combination therapy in antiretroviral na\u00efve adults: 24-week safety and efficacy results from the LATTE study (LAI116482). 14th EACS, 2013, Brussels. Oral abstract PS7.1.
    \nhttp:\/\/www.eacsmobile.org\/libraryEntry\/show\/38282193537098395<\/a><\/li>\n
  2. LATTE Study. Clinicaltrials.gov.
    \n    http:\/\/clinicaltrials.gov\/show\/NCT01641809<\/a><\/li>\n<\/ol>\n
    \u00a0<\/strong><\/div>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Early results were also presented at EACS 2013 for ViiV Healthcare’s follow-up compound to dolutegravir, which currently has the development name GSK-744. [1] Previous results with this integrase inhibitor have reported a sufficiently long half-life with …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[181],"class_list":["post-24027","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-eacs-14-brussels-2013"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/24027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=24027"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/24027\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=24027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=24027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=24027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}